Prelude Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics (NASDAQ:PRLD) reported Q3 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.58) by 22.41 percent. This represents a 28.57 percent increase over losses of $(0.63) per share from the same period last year.
November 01, 2023 | 9:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prelude Therapeutics reported better than expected Q3 losses, which could positively impact the stock in the short term.
Prelude Therapeutics reported Q3 losses of $(0.45) per share, which is better than the analyst consensus estimate of $(0.58). This beat, along with the fact that the losses are less than the same period last year, could lead to a positive reaction in the stock market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100